CYTOKINETICS INC (CYTK) Fundamental Analysis & Valuation

NASDAQ:CYTK • US23282W6057

Current stock price

62.19 USD
+0.06 (+0.1%)
At close:
62.19 USD
0 (0%)
After Hours:

This CYTK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CYTK Profitability Analysis

1.1 Basic Checks

  • In the past year CYTK has reported negative net income.
  • In the past year CYTK has reported a negative cash flow from operations.
  • In the past 5 years CYTK always reported negative net income.
  • In the past 5 years CYTK always reported negative operating cash flow.
CYTK Yearly Net Income VS EBIT VS OCF VS FCFCYTK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M -600M

1.2 Ratios

  • With a Return On Assets value of -55.10%, CYTK perfoms like the industry average, outperforming 44.21% of the companies in the same industry.
Industry RankSector Rank
ROA -55.1%
ROE N/A
ROIC N/A
ROA(3y)-53.67%
ROA(5y)-44.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYTK Yearly ROA, ROE, ROICCYTK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CYTK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYTK Yearly Profit, Operating, Gross MarginsCYTK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. CYTK Health Analysis

2.1 Basic Checks

  • CYTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CYTK has more shares outstanding
  • The number of shares outstanding for CYTK has been increased compared to 5 years ago.
  • CYTK has a worse debt/assets ratio than last year.
CYTK Yearly Shares OutstandingCYTK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
CYTK Yearly Total Debt VS Total AssetsCYTK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B

2.2 Solvency

  • CYTK has an Altman-Z score of -1.98. This is a bad value and indicates that CYTK is not financially healthy and even has some risk of bankruptcy.
  • CYTK has a Altman-Z score (-1.98) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.98
ROIC/WACCN/A
WACC8.13%
CYTK Yearly LT Debt VS Equity VS FCFCYTK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B

2.3 Liquidity

  • A Current Ratio of 4.53 indicates that CYTK has no problem at all paying its short term obligations.
  • CYTK's Current ratio of 4.53 is in line compared to the rest of the industry. CYTK outperforms 52.70% of its industry peers.
  • CYTK has a Quick Ratio of 4.53. This indicates that CYTK is financially healthy and has no problem in meeting its short term obligations.
  • CYTK has a Quick ratio of 4.53. This is comparable to the rest of the industry: CYTK outperforms 54.05% of its industry peers.
Industry RankSector Rank
Current Ratio 4.53
Quick Ratio 4.53
CYTK Yearly Current Assets VS Current LiabilitesCYTK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. CYTK Growth Analysis

3.1 Past

  • The earnings per share for CYTK have decreased strongly by -24.71% in the last year.
  • Looking at the last year, CYTK shows a very strong growth in Revenue. The Revenue has grown by 376.56%.
  • Measured over the past years, CYTK shows a quite strong growth in Revenue. The Revenue has been growing by 9.55% on average per year.
EPS 1Y (TTM)-24.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.05%
Revenue 1Y (TTM)376.56%
Revenue growth 3Y-2.37%
Revenue growth 5Y9.55%
Sales Q2Q%4.89%

3.2 Future

  • CYTK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.08% yearly.
  • The Revenue is expected to grow by 93.42% on average over the next years. This is a very strong growth
EPS Next Y-1.98%
EPS Next 2Y12.41%
EPS Next 3Y17.76%
EPS Next 5Y20.08%
Revenue Next Year18.39%
Revenue Next 2Y118.34%
Revenue Next 3Y114.1%
Revenue Next 5Y93.42%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CYTK Yearly Revenue VS EstimatesCYTK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B
CYTK Yearly EPS VS EstimatesCYTK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. CYTK Valuation Analysis

4.1 Price/Earnings Ratio

  • CYTK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CYTK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYTK Price Earnings VS Forward Price EarningsCYTK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYTK Per share dataCYTK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

  • CYTK's earnings are expected to grow with 17.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.41%
EPS Next 3Y17.76%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CYTK Dividend Analysis

5.1 Amount

  • No dividends for CYTK!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CYTK Fundamentals: All Metrics, Ratios and Statistics

CYTOKINETICS INC

NASDAQ:CYTK (3/18/2026, 8:00:01 PM)

After market: 62.19 0 (0%)

62.19

+0.06 (+0.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners113.58%
Inst Owner Change-12.22%
Ins Owners0.51%
Ins Owner Change1.17%
Market Cap7.66B
Revenue(TTM)88.04M
Net Income(TTM)-784.96M
Analysts80.77
Price Target92.1 (48.09%)
Short Float %12.72%
Short Ratio8.24
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.6%
Min EPS beat(2)-58.24%
Max EPS beat(2)-0.97%
EPS beat(4)2
Avg EPS beat(4)-9.39%
Min EPS beat(4)-58.24%
Max EPS beat(4)20.28%
EPS beat(8)2
Avg EPS beat(8)-10.46%
EPS beat(12)2
Avg EPS beat(12)-19.07%
EPS beat(16)3
Avg EPS beat(16)-12.63%
Revenue beat(2)1
Avg Revenue beat(2)52.63%
Min Revenue beat(2)-46.62%
Max Revenue beat(2)151.88%
Revenue beat(4)3
Avg Revenue beat(4)695.13%
Min Revenue beat(4)-46.62%
Max Revenue beat(4)2646.57%
Revenue beat(8)4
Avg Revenue beat(8)436.13%
Revenue beat(12)5
Avg Revenue beat(12)278.1%
Revenue beat(16)6
Avg Revenue beat(16)342.07%
PT rev (1m)0.59%
PT rev (3m)13.5%
EPS NQ rev (1m)-4.57%
EPS NQ rev (3m)-8.56%
EPS NY rev (1m)-8.28%
EPS NY rev (3m)-16.14%
Revenue NQ rev (1m)-57.84%
Revenue NQ rev (3m)-67.91%
Revenue NY rev (1m)-21.15%
Revenue NY rev (3m)-31.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 87
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.56
EYN/A
EPS(NY)-6.69
Fwd EYN/A
FCF(TTM)-4.34
FCFYN/A
OCF(TTM)-4.14
OCFYN/A
SpS0.71
BVpS-5.36
TBVpS-5.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -55.1%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.67%
ROA(5y)-44.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 245.01%
Cap/Sales 28.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.53
Quick Ratio 4.53
Altman-Z -1.98
F-Score3
WACC8.13%
ROIC/WACCN/A
Cap/Depr(3y)99.3%
Cap/Depr(5y)527.3%
Cap/Sales(3y)22.71%
Cap/Sales(5y)29.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.05%
EPS Next Y-1.98%
EPS Next 2Y12.41%
EPS Next 3Y17.76%
EPS Next 5Y20.08%
Revenue 1Y (TTM)376.56%
Revenue growth 3Y-2.37%
Revenue growth 5Y9.55%
Sales Q2Q%4.89%
Revenue Next Year18.39%
Revenue Next 2Y118.34%
Revenue Next 3Y114.1%
Revenue Next 5Y93.42%
EBIT growth 1Y-14.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.32%
EBIT Next 3Y11.93%
EBIT Next 5Y29.57%
FCF growth 1Y-33.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.83%
OCF growth 3YN/A
OCF growth 5YN/A

CYTOKINETICS INC / CYTK Fundamental Analysis FAQ

What is the fundamental rating for CYTK stock?

ChartMill assigns a fundamental rating of 2 / 10 to CYTK.


What is the valuation status for CYTK stock?

ChartMill assigns a valuation rating of 0 / 10 to CYTOKINETICS INC (CYTK). This can be considered as Overvalued.


Can you provide the profitability details for CYTOKINETICS INC?

CYTOKINETICS INC (CYTK) has a profitability rating of 0 / 10.


What is the expected EPS growth for CYTOKINETICS INC (CYTK) stock?

The Earnings per Share (EPS) of CYTOKINETICS INC (CYTK) is expected to decline by -1.98% in the next year.